Organogenesis Holdings Inc. (NASDAQ:ORGO) shares surged about 20% on Tuesday after the company reported that its PuraPly AM ...

DFU wound closure at 12 weeksRCT compared PuraPly®AM plus standard of care to standard of care aloneResults strengthen existing clinical evidence supporting future coverage CANTON, Mass., April 06, ...

The market has shown robust performance, rising 3.1% over the last week and 27% over the past year, with earnings expected to grow by 16% annually in the coming years. In light of these conditions, ...

Shares of Organogenesis Holdings were higher after the company said its product for non-healing diabetic foot ulcers met its primary endpoint in a recent trial. The stock rose 30%, to $2.91, in ...

Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) ...

Organogenesis is a solid player in the surgical care product market. Over its long existence, it has developed an important slate of core competencies. Small-cap biotech is a risky area, none more so ...

Organogenesis Holdings Inc. ORGO shares are up during Tuesday’s premarket session following the company’s announcement of achieving the primary endpoint in a randomized controlled trial evaluating ...

Investing.com -- Organogenesis Holdings Inc. (NASDAQ:ORGO) shares rose 20% Tuesday after the company announced its PuraPly AM product achieved the primary endpoint in a randomized controlled trial for ...

Organogenesis Holdings Inc. looks undervalued at distressed multiples; new DFU RCT data supports coverage despite 2026 CMS ...

Robust 218-patient RCT demonstrates statistically superior frequency of wound closure at 12 weeks compared to standard of care (p=.04) Organogenesis believes published study satisfies requirements for ...

Organogenesis saw revenue and net income drop year over year. The company withdrew annual guidance. Organogenesis is disputing that some of its products should have been excluded from coverage by ...

Organogenesis focuses on advanced wound products. The company's second-quarter revenue and net income were down year over year. The company withdrew its full-year guidance in its second-quarter report ...